In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Hurry-Up-And-Wait Signal For Clinical Whole Genome Sequencing?

Executive Summary

The debate over whether whole-genome sequencing (WGS) can compete with targeted sequencing approaches ratcheted up a notch when WGS service provider Complete Genomics tabled its plan to double capacity until, it said, “demand for clinical-grade genomes supports expansion.” But data interpretation may prove to be as much of a gating factor as sequencing speed or scope.

You may also be interested in...



A Researcher’s Hope For Sequencing: Rare Genetic Variants Yield New Drugs

Columbia University Professor Wendy Chung’s work on identifying the causative mutations underlying ultra-rare diseases such as hereditary pulmonary hypertension puts a real-world perspective on pharma’s increasing interest in genomic analysis as a tool for drug discovery.

Molecular Diagnostics Ushers In New Era Of Prenatal Testing

The recent launch of several noninvasive gene-based tests for Down syndrome and other fetal chromosomal abnormalities is poised to upend current prenatal screening practices and potentially usher in a new, multibillion-dollar market opportunity in the process. These new tests employ next-generation gene sequencing, along with advanced, risk-based computer algorithms, to detect and characterize fetal genetic abnormalities using the DNA present in a maternal blood sample. And because they are actually able to “interrogate” the DNA, they represent a huge technological advance over the current standard-of-care for prenatal screening.

Trends In Diagnostics 2011

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel